{"nctId":"NCT03689712","briefTitle":"ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients","startDateStruct":{"date":"2018-10-03","type":"ACTUAL"},"conditions":["Oral Mucositis"],"count":455,"armGroups":[{"label":"GC4419 (avasopasem manganese) 90 mg","type":"EXPERIMENTAL","interventionNames":["Drug: GC4419 90mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"GC4419 90mg","otherNames":["avasopasem manganese"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* squamous cell carcinoma of the head and neck\n* treatment plan to receive IMRT delivered as single daily fractions of 2.0 to 2.2 Gy with a cumulative radiation dose of 60-72 Gy\n* Treatment plan to receive standard cisplatin monotherapy\n* Age 18 years or older\n* Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2\n* Adequate hematologic, renal and liver function\n* Negative serum pregnancy test\n* Use of effective contraception\n\nExclusion Criteria:\n\n* Tumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, or salivary glands\n* Metastatic disease\n* Prior radiotherapy to the region of the study cancer or adjacent anatomical\n* Prior induction chemotherapy\n* Receiving any approved or investigational anti-cancer agent other than those provided for in this study\n* Concurrent participation in another interventional clinical study\n* Inability to eat soft solid food at baseline\n* Malignant tumors other than HNC within the last 5 years\n* Active infectious disease excluding oral candidiasis\n* Presence of oral mucositis at baseline\n* Known history of HIV or active hepatitis B/C\n* Female patients who are pregnant or breastfeeding\n* Known allergies or intolerance to cisplatin and similar platinum-containing compounds\n* Requirement for concurrent treatment with nitrates or other drugs that may create a risk for a precipitous decrease in blood pressure","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Incidence of Severe Oral Mucositis","description":"Cumulative incidence of severe oral mucositis is defined as the proportion of subjects with any occurrence of WHO Grade 3 to 4 OM, during the Study Treatment Period. Incidence of severe OM is defined as any occurrence of WHO Grade 3 or 4 OM through the last IMRT fraction after the start of IMRT. Incidence was imputed using multiple imputation for subjects with incomplete follow-up for severe OM through 60 Gy who did not have an occurrence of severe OM before the last IMRT fraction.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"64.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":81,"n":241},"commonTop":["Lymphopenia","Nausea","Fatigue","Oropharyngeal Pain","Constipation"]}}}